This TCR (hereafter referred to as m1G4 TCR) was initially identified from an NY-ESO-1 (New York esophageal squamous cell carcinoma 1) positive melanoma patient by our group.14 NY-ESO-1 is a highly immunogenic, tumor-specific human germ cell antigen of the MAGE-1 (Melanoma-associated antigen 1) family that is a promising vaccine and cell therapy target for tumor immunotherapy.15 NY-ESO-1 is 180 residue protein composed of a hydrophobic C-terminus and glycine-rich N-terminus. Here, MAGEA1 is linked to neoplasm.